Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05366166
Title Pembrolizumab Plus Olaparib in LA-HNSCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

hypopharynx cancer

oral cavity cancer

laryngeal squamous cell carcinoma

oropharynx cancer

Therapies

Cisplatin + Olaparib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.